We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A congressional investigation into consulting arrangements and other undisclosed financial relationships between drugmakers and staff at the National Institutes of Health (NIH) has resulted in a demand for more information about a loophole that has allowed institute directors and other top officials to escape disclosure requirements.